Women's preferences toward attributes of local estrogen therapy for the treatment of vaginal atrophy

Maturitas

Volumn 74, Issue 3, 2013, Pages 259-263

  Mattsson, Lars Åke ^a   Ericsson, Åsa ^b   Bøgelund, Mette ^c   Maamari, Ricardo ^d  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Novo Nordisk Scandinavia   (Sweden)

^c Incentive Partners ^*  (Denmark)

^d NOVO NORDISK INC   (United States)

Author keywords

Local estrogen therapy; Menopause; Preference; Survey; Vaginal atrophy; Willingness to pay

Indexed keywords

ESTROGEN; AGENTS USED INTRAVAGINALLY; DRUG CARRIER; TABLET;

ADULT; AGED; ARTICLE; ESTROGEN SYNTHESIS; ESTROGEN THERAPY; FEMALE; HEALTH SURVEY; HUMAN; LOCAL ESTROGEN THERAPY; LOCAL THERAPY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT PREFERENCE; POSTMENOPAUSE; QUESTIONNAIRE; VAGINA; VAGINA ATROPHY; ATROPHY; ATTITUDE TO HEALTH; DEVICES; DISPOSABLE EQUIPMENT; DRUG EFFECTS; DYSPAREUNIA; HEALTH CARE COST; MENOPAUSE; MIDDLE AGED; PATHOLOGY; PROCEDURES; SYRINGE; TABLET; VAGINAL DISEASES;

AGED; ATROPHY; ATTITUDE TO HEALTH; DISPOSABLE EQUIPMENT; DRUG CARRIERS; DYSPAREUNIA; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HEALTH CARE COSTS; HUMANS; MENOPAUSE; MIDDLE AGED; PATIENT PREFERENCE; POSTMENOPAUSE; SURVEYS AND QUESTIONNAIRES; SYRINGES; TABLETS; VAGINA; VAGINAL CREAMS, FOAMS, AND JELLIES; VAGINAL DISEASES;

EID: 84884213419     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2012.12.004     Document Type: Article

References (28)

1. Sturdee DW, Panay N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010;13(December (6)):509-22.
2. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. The Journal of Sexual Medicine 2009;6(August (8)):2133-42.
3. Archer DF. Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 2010;17(January-February (1)):194-203.
4. Smith RN, Studd JW. Recent advances in hormone replacement therapy. British Journal of Hospital Medicine 1993;49(June (11)):799-808.
5. Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA) - results from an international survey. Climacteric 2012;15(February (1)):36-44.
6. Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 2008;15(July-August (4 Pt 1)):661-6.
7. North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17(March (2)):242-55.
8. Nappi RE, Polatti F. The use of estrogen therapy in women's sexual functioning (CME). The Journal of Sexual Medicine 2009;6(March (3)):603-16.
9. Dugal R, Hesla K, Sordal T, Aase KH, Lilleeidet O, Wickstrom E. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy. Acta Obstetricia et Gynecologica Scandinavica 2000;79(April (4)):293-7.
10. Calaf Alsina J. Perception and use of local hormone replacement therapy. European Menopause Journal 1996;3(2 Suppl.):85-9.
11. Shulman LP, Portman DJ, Lee WC, et al. A retrospective managed care claims data analysis of medication adherence to vaginal estrogen therapy: implications for clinical practice. Journal of Women's Health (Larchmt) 2008;17(May (4)):569-78.
12. Ryan M, Hughes J. Using conjoint analysis to assess women's preferences for miscarriage management. Health Economics 1997;6(May-June (3)):261-73.
13. Lancaster K. Consumer demand: a new approach. New York: Columbia University Press; 1971.
14. Barker N. A practical introduction to the bootstrap using the SAS system. Wallingford, UK: Oxford Pharmaceutical Sciences; 2005. Available at http://www.lexjansen.com/phuse/2005/pk/pk02.pdf.
15. Aristides M, Weston AR, FitzGerald P, Le Reun C, Maniadakis N. Patient preference and willingness-to-pay for Humalog Mix25 relative to Humulin 30/70: a multicountry application of a discrete choice experiment. Value in Health 2004;7(July-August (4)):442-54.
16. Bryan S, Buxton M, Sheldon R, Grant A. Magnetic resonance imaging for the investigation of knee injuries: an investigation of preferences. Health Economics 1998;7(November (7)):595-603.
17. Davey P, Grainger D, MacMillan J, Rajan N, Aristides M, Dobson M. Economic evaluation of insulin lispro versus neutral (regular) insulin therapy using a willingness-to-pay approach. Pharmacoeconomics 1998;13(March (3)):347-58.
18. Dranitsaris G, Longo CJ, Grossman LD. The economic value of a new insulin preparation, Humalog Mix 25. Measured by a willingness-to-pay approach. Pharmacoeconomics 2000;18(September (3)):275-87.
19. Ryan M, McIntosh E, Shackley P. Methodological issues in the application of conjoint analysis in health care. Health Economics 1998;7(June (4)):373-8.
20. Murphy JJ, Allen PG, Stevens TH, Weatherhead D. A meta-analysis of hypothetical bias in stated preference. Environmental and Resource Economics 2005;30(March (3)):313-25.
21. Frykblom P. Hypothetical question modes and real willingness to pay. Journal of Environmental Economics and Management 1997;34(November (3)):275-87.
22. Zethraeus N, Johannesson M, Henriksson P, Strand RT. The impact of hormone replacement therapy on quality of life and willingness to pay. British Journal of Obstetrics and Gynaecology 1997;104(October (10)):1191-5.
23. Zethraeus N. Willingness to pay for hormone replacement therapy. Health Economics 1998;7(February (1)):31-8.
24. Tambour M, Zethraeus N. Nonparametric willingness-to-pay measures and confidence statements. Medical Decision Making 1998;18(July-September (3)):330-6.
25. Barner JC, Branvold A. Patients' willingness to pay for pharmacist-provided menopause and hormone replacement therapy consultations. Research in Social and Administrative Pharmacy 2005;1(March (1)):77-100.
26. Rasch A, Hodek JM, Runge C, Greiner W. Determinants of willingness to pay for a new therapy in a sample of menopausal-aged women. Pharmacoeconomics 2009;27(8):693-704.
27. Nappi RE, Kokot-Kierepa M. Women's voices in the menopause: results from an international survey on vaginal atrophy. Maturitas 2010;67(November (3)):233-8.
28. Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17βestradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000;7(May-June (3)): 156-61.